Ross Andrew Soo
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 171
- Lung Cancer Diagnosis and Treatment 32
- Gastric Cancer Management and Outcomes 12
- Oncology 134
- Lung Cancer Research Studies 37
- Colorectal Cancer Treatments and Studies 37
- Cancer Immunotherapy and Biomarkers 37
- Co-authors
- Byoung Chul Cho (44 shared papers)Nicholas L. X. Syn (13 shared papers)Tony S.K. Mok (20 shared papers)Richie Soong (24 shared papers)Sai‐Hong Ignatius Ou (20 shared papers)Michele W.L. Teng (1 shared paper)Sun Min Lim (14 shared papers)Daniel Shao-Weng Tan (8 shared papers)
- Journals
- Annals of Oncology (48 papers)Journal of Thoracic Oncology (35 papers)Lung Cancer (25 papers)Journal of Clinical Oncology (9 papers)Future Oncology (9 papers)
- Partner nations
- SingaporeUnited StatesSouth Korea
In The Last Decade
Ross Andrew Soo
305 papers receiving 14.9k citations
Ross Andrew Soo's Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 7.1k
- Pulmonary and Respiratory Medicine 6.5k
- Cancer Research 2.3k
- Molecular Biology 4.1k
- Immunology 1.2k
Countries citing papers authored by Ross Andrew Soo
This map shows the geographic impact of Ross Andrew Soo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross Andrew Soo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross Andrew Soo more than expected).
Fields of papers citing papers by Ross Andrew Soo
This network shows the impact of papers produced by Ross Andrew Soo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross Andrew Soo. The network helps show where Ross Andrew Soo may publish in the future.
Co-authors
The 25 scholars most cited alongside Ross Andrew Soo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 314 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study Hit paper breakdown → | 2018 | 649 |
| 2 | Isolation and retrieval of circulating tumor cells using centrifugal forces Hit paper breakdown → | 2013 | 639 |
| 3 | De-novo and acquired resistance to immune checkpoint targeting Hit paper breakdown → | 2017 | 616 |
| 4 | Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis Hit paper breakdown → | 2012 | 578 |
| 5 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 496 |
| 6 | A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Hit paper breakdown → | 2012 | 494 |
| 7 | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer Hit paper breakdown → | 2013 | 493 |
| 8 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 473 |
| 9 | 2019 | 316 | |
| 10 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial Hit paper breakdown → | 2019 | 300 |
| 11 | 2018 | 249 | |
| 12 | 2018 | 233 | |
| 13 | 2020 | 227 | |
| 14 | 2018 | 221 | |
| 15 | 2020 | 208 | |
| 16 | 2015 | 193 | |
| 17 | Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study Hit paper breakdown → | 2024 | 188 |
| 18 | 2012 | 181 | |
| 19 | 2014 | 171 | |
| 20 | 2014 | 169 |
About Ross Andrew Soo
Ross Andrew Soo is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 314 papers that have together received 15.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (171 papers), Lung Cancer Research Studies (37 papers), Colorectal Cancer Treatments and Studies (37 papers), Cancer Immunotherapy and Biomarkers (37 papers), Lung Cancer Diagnosis and Treatment (32 papers), Cancer Genomics and Diagnostics (30 papers), Cancer therapeutics and mechanisms (15 papers) and Gastric Cancer Management and Outcomes (12 papers). The work is most often cited by research in Oncology (7.1k citations), Pulmonary and Respiratory Medicine (6.5k citations), Cancer Research (2.3k citations), Molecular Biology (4.1k citations) and Immunology (1.2k citations). Ross Andrew Soo has collaborated with scholars based in Singapore, United States and South Korea. Frequent co-authors include Byoung Chul Cho, Nicholas L. X. Syn, Tony S.K. Mok, Richie Soong, Sai‐Hong Ignatius Ou, Michele W.L. Teng, Sun Min Lim, Daniel Shao-Weng Tan, Darren Wan-Teck Lim and Majid Ebrahimi Warkiani. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Journal of Clinical Oncology and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.